Tunisia Hatem Hachicha is Pfizer’s former manager for Tunisia, Libya and French-speaking African countries. He believes Tunisia’s pharmaceutical industry development will be achieved through internationalization and a shift towards biosimilars drugs. Co-founder of SEPHIRE and an active member of the Tunisian healthcare community, he stresses that one of the challenges in…
Canada Alok Kanti, president and CEO of Bayer Canada, draws upon his 27 years of international experience with Bayer to discuss the strategic significance of the Canadian affiliate to Bayer’s global operations, the challenges and opportunities he sees for industry-government collaboration, and the need for the country to promote a more…
Canada Michael Tremblay, president and CEO of Astellas Pharma Canada, Inc., draws upon his four decades of experience within the Canadian pharmaceutical industry to discuss his thoughts on the need for Canada to move away from a ‘silo-ed’ approach to healthcare spending, the value that Astellas has been bringing to patients…
Tunisia Khalil Laabidi, general manager of the Tunisian Foreign Investment Promotion Agency (FIPA) since 2014, discusses his organization’s responsibility for attracting foreign investment in line with the government’s objective of economic transformation, increasing technology transfer and making Tunisia a capital-intensive economy. What is the role of FIPA and how has it…
Canada Douglas Clark, Executive Director of the Patented Medicine Prices Review Board (PMPRB), Canada’s federal price regulator for patented medicines, highlights the PMPRB’s mandate to protect consumers against excessive prices for patented drugs, the rationale behind the recent proposed changes to their guidelines, and the role PMPRB can play within Canada’s…
Brazil Fabio Bussinger, partner-director of the Pharmaceutical Institute of Operational Governance (IFGO) in Brazil, documents the market needs that prompted him to set up Benchmarking Operational Competitiveness (BCO) Farma, a long-awaited benchmarking panel focused on operational excellence that has already delivered great outcomes to its members. You were operations vice president…
Canada Jim Keon, President of the CGPA, discusses how the Canadian generics industry is adapting to the current period of political transition and how it engages in talks with the government and other stakeholders to educate them about the costly and complex process of generic drug production. Jim, we had the…
Austria Dr. Dietmar Katinger, CEO of Polymun, an Austrian R&D and contract manufacturing company, discusses the challenges CMO companies face within the Austrian market and increasing industry regulations. He also provides an overview of Austria’s ability to accelerate its stature as an innovation hub. Could you introduce the scope of the…
Canada Jonathan Ross Goodman, founder and CEO of Knight Therapeutics Inc., discusses the unique backstory behind the founding of the company, coming on the heels of the sale of Paladin Labs Inc., his previous company, for CAD 3.2 billion, the cycling accident that left him brain-damaged but more committed than ever…
Colombia Sandra Ramirez, General Manager of Bristol-Myers Squibb Colombia & Mexico, reveals valuable insights into the long-standing presence of BMS in Colombia, marked by a continuous dedication to increase access to medicine, the gradual development of their immuno-oncology pipeline and the creation of an inclusive culture formed by satisfied employees. Ms.…
Colombia David Leclercq, general manager of Mundipharma Colombia, reveals his passion for both the Colombian affiliate and the welfare of the Colombian people and gives insight into operating a new pharmaceutical outfit in a highly transformative healthcare environment. You were appointed General Manager in Colombia back in 2014; what have been…
Bulgaria Assena Stoimenova, member of the management board of the European Medicines Agency (EMA) and executive director of the Bulgarian Drug Agency (BDA), explains the Agency’s evolution under her tenure as well as her commitment to ensuring that the BDA remains predictable, transparent and fair, being fully focused on safeguarding patients…
See our Cookie Privacy Policy Here
